Is Abeona Therapeutics Inc. (NASDAQ:ABEO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Abeona Therapeutics Inc. at current levels.
ZEVASKYN's commercial ramp is the whole story, and the market is treating a real launch like a science project.
Where ABEO is headed
By mid-2027, Abeona will either be the clearest example of a small-cap gene therapy company that actually made the transition to commercial, or a cautionary tale about how brutal ultra-rare launches can be even when the science works. Right now the setup leans toward the first outcome. ZEVASKYN is on the market for recessive dystrophic epidermolysis bullosa (RDEB), it has a Priority Review Voucher already monetized, and the treatment center network is being built out in the way these launches actually scale: slowly, one qualified surgical site at a time, then all at once as reimbursement pathways get cleaner.
Read the full Compass Direction on ABEO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $6.09).
See the full ABEO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Abeona Therapeutics Inc. (NASDAQ:ABEO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Abeona Therapeutics Inc. at current levels. ZEVASKYN's commercial ramp is the whole story, and the market is treating a real launch like a science project.
What is ABEO's Compass Score?
Abeona Therapeutics Inc. scores 75/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for ABEO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ABEO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.